Suspension of Oncology Randomized Clinical Trials during the COVID-19 Pandemic: A Cross-Sectional Evaluation of COVID-Related Suspensions.

Rashid K Sayyid, Anthony Hiffa, Phillip Woodruff, Michael D Oberle, Joshua H Lambert, Martha K Terris, Christopher J D Wallis, Zachary Klaassen

Cancer investigation 2022 Oct

filter terms:

We conducted a cross-sectional analysis of ClinicalTrials.gov-registered oncology randomized controlled trials between September 2019 and December 2021 to identify predictors of trial suspensions. The dataset included 1,183 oncology trials, of which 384 (32.5%) were suspended. COVID-19 accounted for 47 (12.2%) suspensions. Trials that were single center- or US-based had higher odds of COVID-19 (ORs: 3.85 and 2.48, 95% CIs: 1.60-11.50 and 1.28-4.93, respectively) or any-reason suspensions (ORs: 2.33 and 2.04, 95% CIs: 1.46-3.45 and 1.40-2.76, respectively). Phase two (OR 1.27), three (OR 6.45) and four trials (OR 11.5) had increased odds of COVID-19 suspensions, compared to phase one trials.

Citation

Rashid K Sayyid, Anthony Hiffa, Phillip Woodruff, Michael D Oberle, Joshua H Lambert, Martha K Terris, Christopher J D Wallis, Zachary Klaassen. Suspension of Oncology Randomized Clinical Trials during the COVID-19 Pandemic: A Cross-Sectional Evaluation of COVID-Related Suspensions. Cancer investigation. 2022 Oct;40(9):743-749